ピロヘプチン 化学特性,用途語,生産方法
効能
パーキンソン病治療薬, ムスカリン受容体拮抗薬
Originator
Trimol,Fujisawa ,Japan ,1974
Manufacturing Process
(1) To 3.8 g of 2-methyl-3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5ylidene)-1-pyrroline, there were added 8 g of ethyl iodide. This mixture was placed into a closed vessel and heated at 80°C in a water-bath for one hour. After completing the reaction, the reaction mixture was cooled and the unreacted ethyl iodide was distilled off to yield 5.5 g of 1-ethyl-2methyl-3(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ylidene)-1-pyrrolinium iodide in the form of yellow crystals. These crystals were recrystallized from a mixture of acetone and ether to yield yellow needles of the melting point 223°C.
(2)1-Ethyl-2-methyl-3-(10,11)-dihydro-5H-dibenzo[a,d]cycloheptene-5ylidene)-1-pyrroliniumiodide (4.7 g) was dissolved in 7 cc of methanol. To this solution there were added 1.4 g of sodium boron hydride within about 80 minutes with stirring and stirring of the solution was continued for two hours to complete the reaction. The reaction mixture was acidified with 10% aqueous hydrochloric acid solution and then the methanol was distilled off. The residual solution was alkalized with 20% aqueous sodium hydroxide solution and extracted with ether. The ether layer was dried over magnesium sulfate and the ether was distilled off. The resulting residue was further distilled under reduced pressure to yield 2.0 g of 1-ethyl-2-methyl-3-(10,11)dihydro-5H-dibenzo[a,d]cycloheptene-5-ylidene)pyrrolidine (boiling point 167°C/4 mm Hg.).
Therapeutic Function
Antiparkinsonian
ピロヘプチン 上流と下流の製品情報
原材料
準備製品